In re Acadia Pharmaceuticals Inc. Stockholder Derivative Litigation

UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF CALIFORNIA 10 TIFFANY BARNEY, derivatively on Case No. 20-cv-00238-BAS-JLB behalf of ACADIA

PHARMACEUTICALS INC., ORDER:

12 Plaintiff, (1) DENYING WITHOUT PREJUDICE PLAINTIFF’S v. MOTION TO SEAL [ECF No. 3]; 14 STEPHEN R. DAVIS, et al.,

AND

15 Defendants. (2) GRANTING JOINT MOTION TO CONTINUE STAY PROCEEDINGS [ECF No. 10] 17 On February 7, 2020, Plaintiff filed a verified stockholder derivative complaint for violations of securities law, breach of fiduciary duty, waste of corporate assets, and unjust enrichment (“Complaint”). (ECF No. 1.) The Court addresses Plaintiff’s Motion to Seal (ECF No. 3) and the parties’ Joint Motion to Stay Proceedings (ECF No. 10) below. I. MOTION TO SEAL Plaintiff has moved to file the Complaint under seal on the basis that Defendant ACADIA Pharmaceuticals, Inc. (“ACADIA”) previously represented that certain information used in the Complaint constituted confidential business…